Cost Information Not Available in Clinical Evidence
The provided evidence does not contain specific pricing information for Dupixent (dupilumab) for atopic dermatitis treatment. The clinical guidelines and FDA labeling focus on dosing regimens rather than costs, and the pharmacoeconomic studies reference cost-effectiveness analyses without providing actual retail or wholesale acquisition prices 1.
What the Evidence Shows About Dosing (Not Cost)
Standard Adult Dosing for Atopic Dermatitis
According to FDA labeling, the recommended regimen is 1:
- Loading dose: 600 mg (two 300 mg injections) at initiation
- Maintenance: 300 mg every 2 weeks (Q2W) thereafter
This translates to:
- Year 1: 27 injections total (2 for loading dose + 25 maintenance doses)
- Year 2 and beyond: 26 injections annually
Cost References from Economic Studies
The research evidence provides only historical cost estimates used in modeling studies:
- One 2017 analysis estimated an annual maintenance price range of $28,770-$39,940 to be cost-effective at standard thresholds 2
- A 2018 study calculated total dupilumab drug costs at $267,800 over a patient's lifetime in their model 3
- A 2026 study comparing dupilumab to lebrikizumab in Italy noted dupilumab was more cost-effective but did not provide actual acquisition costs 4
These are modeling estimates from years past and do not reflect current actual pricing.
Where to Find Current Pricing
For actual current costs, you must:
- Contact the manufacturer (Regeneron/Sanofi) directly
- Check wholesale acquisition cost (WAC) databases
- Verify patient-specific insurance coverage and copay assistance programs
- Consult pharmacy benefit managers for negotiated rates
Important caveat: Out-of-pocket costs vary dramatically based on insurance coverage, manufacturer copay cards, and patient assistance programs, making any single "cost" figure potentially misleading for individual patients.